

1 Cerebral Organoids Containing an *AUTS2* Missense Variant

2 Model Microcephaly

3
4 Summer R. Fair¹, Wesley Schwind¹, Dominic Julian¹, Alecia Biel¹, Swetha
5 Ramadesikan¹, Jesse Westfall¹, Katherine E. Miller¹, Meisam Naeimi Kararoudi^{2,5}, Scott
6 E. Hickey^{4,5}, Theresa Mihalic Mosher¹, Kim L. McBride^{1,3,4,5}, Reid Neinast³, James
7 Fitch¹, Dean Lee^{2,5}, Peter White^{1,5}, Richard K. Wilson^{1,5}, Tracy A. Bedrosian^{1,5}, Daniel
8 C. Koboldt^{1,5}, Mark E. Hester^{1,5,6}

9 Affiliations:

10 ¹The Steve and Cindy Rasmussen Institute for Genomic Medicine, ²Center for
11 Childhood Cancer and Blood Diseases, ³Center for Cardiovascular Research, ⁴Division
12 of Genetic and Genomic Medicine, Abigail Wexner Research Institute at Nationwide
13 Children's Hospital, Columbus, Ohio, USA; ⁵Department of Pediatrics, The Ohio State
14 University College of Medicine, Columbus, Ohio, USA; ⁶Department of Neuroscience,
15 The Ohio State University Wexner Medical Center, Columbus, Ohio, USA

16 Corresponding Author:

17
18 Mark E. Hester, Ph.D.
19 575 Children's Crossroad
20 Columbus, Ohio 43205-2716
21 Phone: 614-355-6805
22 Fax: 614-355-6675
23 Email: Mark.Hester@NationwideChildrens.org

24 Co-Corresponding Author:

25
26 Daniel C. Koboldt, MS
27 575 Children's Crossroad
28 Columbus, Ohio 43205-2716
29 Phone: 614-722-0520
30 Email: Daniel.Koboldt@NationwideChildrens.org

31 **Figures: 6**

32 **Supplemental Figures: 6**

33 **Supplemental Tables: 4**

36 **ABSTRACT**

37 Variants in the *AUTS2* gene are associated with a broad spectrum of neurological
38 conditions characterized by intellectual disability, microcephaly, and congenital brain
39 malformations. Here, we use a human cerebral organoid (CO) model to investigate the
40 pathophysiology of a heterozygous *de novo* missense *AUTS2* variant identified in a
41 patient with multiple neurological impairments including primary microcephaly and
42 profound intellectual disability. Proband COs exhibit reduced growth, deficits in neural
43 progenitor cell (NPC) proliferation and disrupted NPC polarity within ventricular zone-
44 like regions compared to control COs. We used CRISPR-Cas9-mediated gene editing to
45 correct this variant and demonstrate rescue of impaired organoid growth and NPC
46 proliferative deficits. Single-cell RNA sequencing revealed a marked reduction of G1/S
47 transition gene expression and alterations in WNT- β -Catenin signaling within proband
48 NPCs, uncovering a novel role for *AUTS2* in NPCs during human cortical development.
49 Collectively, these results underscore the value of COs to uncover molecular
50 mechanisms underlying *AUTS2* syndrome.

51

52 **KEYWORDS:** *AUTS2* syndrome, cerebral organoids, CRISPR Cas9, microcephaly,
53 neurodevelopmental disorder, neural progenitor cell

54

55 INTRODUCTION

56 The autism susceptibility candidate 2 (*AUTS2*) gene was first identified and found
57 disrupted as a result of a balanced translocation event (t7;20)¹ in a pair of monozygotic
58 twins with autism spectrum disorder (ASD). Subsequent clinical reports suggest
59 pathological *AUTS2* variants are more closely associated with intellectual disability (ID)
60 rather than directly contributing to classical features associated with ASD. *AUTS2* is a
61 highly conserved gene that spans 1.2Mb on chromosome 7q11.22 and is comprised of
62 19 coding exons with a predicted full-length protein of 1,259 amino acids (Fig. 1e).
63 Biochemical studies have shown that *AUTS2*, in association with Casein Kinase 2
64 (CK2), form a polycomb repressive complex 1 (PRC1-*AUTS2*) which activates rather
65 than represses transcription through recruitment of p300². There are several reported
66 isoforms of *AUTS2*, including full-length and various C-terminal isoforms, that are
67 expressed throughout brain development^{3,4}. Previous studies have shown deletions
68 within the C-terminus isoform spanning exons 9-19 are associated with a severe
69 neurocognitive phenotype^{3,5}. Other studies have demonstrated several C-terminal
70 isoforms, which are expressed at internal transcriptional start sites in exons 6 and 9,
71 have critical roles during neuronal differentiation^{3,4,6}.

72 *AUTS2* variants are associated with a broad spectrum of clinical features,
73 including low birth weight, feeding difficulties, intellectual disability, microcephaly,
74 seizures, brain malformations and mild dysmorphic craniofacial features that are
75 collectively known as *AUTS2* syndrome⁵. *AUTS2* variants are additionally associated
76 with a host of other neurological conditions such as addiction disorders^{7,8}, epilepsy⁹,
77 schizophrenia^{10,11}, attention deficit hyperactivity disorder¹² and dyslexia¹³. The diverse
78 disease manifestations of *AUTS2* variants within the brain underscore the importance of
79 elucidating its role in neurodevelopment.

80 Animal studies have demonstrated a putative role for *AUTS2* in transcriptional
81 activation, RNA metabolism¹⁴, and cytoskeletal regulation within the central nervous
82 system (CNS)^{2,6}. *Auts2* knockdown zebrafish models exhibit overall stunted growth
83 compared to controls, with notable reductions in the forebrain, midbrain and
84 cerebellum^{3,15}. Various rodent models of *AUTS2* disruption show reductions in the
85 cerebellum^{4,6,16} and dentate gyrus¹⁴. However, these rodent models do not display a

86 microcephalic phenotype, which has hampered our understanding of molecular
87 mechanisms that cause human microcephaly in AUTS2 syndrome. The emergence of
88 human-based model systems of the developing brain such as cerebral organoids (COs)
89 has refined our understanding of the mechanisms controlling human cortical
90 development. In particular, these model systems have revealed human-specific diversity
91 in progenitor quiescence, architecture, and subtypes that recapitulate morphological
92 features of the developing human fetal cortex¹⁷⁻²⁰. Several studies modeling primary
93 microcephaly using COs arising from variants in *CDK5RAP2*²¹, *WDR62*²², and *NARS1*²³
94 have uncovered important insights into disease mechanisms²⁴. Cumulatively, these
95 reports show cellular deficits in cell cycle progression and cilia formation in apical neural
96 progenitor cells (NPCs) concomitant with reduced cortical expansion in COs^{21-23,25,26}.

97 Here we describe a human CO model to investigate the pathophysiology of a
98 heterozygous *de novo* missense *AUTS2*^{T534P} variant identified in a patient with several
99 neurological impairments, including primary microcephaly and profound intellectual
100 disability. Since the majority of all reported pathogenic/likely-pathogenic missense
101 variants cluster near our patient's variant, we envisioned a CO model of the *AUTS2*^{T534P}
102 variant would allow us to explore disease mechanisms underlying AUTS2 syndrome.
103 Our results demonstrate *AUTS2*^{T534P} COs show an impaired growth trajectory compared
104 to controls, which recapitulates the patient's microcephaly and thus provides a novel
105 model to investigate causal disease mechanisms. Further investigation of proband COs
106 using immunohistochemical techniques revealed reduced NPC proliferation and
107 irregular apical NPC polarity in neural rosettes. To validate whether the proband's CO
108 phenotypes are causal to the *AUTS2*^{T534P} variant, we used CRISPR-Cas9 homology
109 directed repair to restore the wild-type sequence (c.1600C>A) and demonstrate
110 phenotypic rescue of impaired organoid growth and proliferative deficits in NPCs
111 compared to proband COs. Single-cell RNA sequencing (scRNA-seq) of proband COs
112 showed an underrepresentation of progenitors enriched in expression of G1/S transition
113 genes as well as dysregulated gene expression signatures associated with WNT-β-
114 Catenin signaling, which were rescued in gene corrected (GC) control COs. Collectively,
115 these results demonstrate a novel role for AUTS2 during early human cortical

116 development within NPCs and emphasize the value of COs to uncover pathogenic
117 mechanisms underlying AUTS2 syndrome.

118

119 **RESULTS**

120 **Identification of a *de novo* missense variant in the *AUTS2* gene.**

121 We report a preschool female who presented with profound intellectual disability,
122 cerebellar hypoplasia, epilepsy, and dysmorphic features (Fig.1a). An MRI of the
123 patient's brain showed enlarged ventricles consistent with cerebral volume loss as well
124 as small cerebellar hemispheres and vermis (Fig.1b-c). Extensive clinical genetic testing
125 was performed on the patient that included karyotype and SNP microarray analysis,
126 biochemical testing for congenital disorders of glycosylation and Smith-Lemli-Opitz
127 syndrome, and DNA methylation testing for Prader-Willi/Angelman syndrome. All of
128 these tests were interpreted by the clinical care team as non-diagnostic. The patient and
129 her parents were then enrolled in an IRB-approved research study for further genomic
130 analysis.

131 To investigate whether the patient's symptoms resulted from underlying genetic
132 causes, whole-genome sequencing (WGS) was performed on the patient and healthy
133 parents (Supplementary Table 1). Our analysis uncovered two candidate-coding
134 variants in the patient without corresponding genetic alterations in the parents,
135 suggesting these variants arose *de novo*. The first candidate was a mosaic splice site
136 variant *TULP3* (NM_003324.4:c.253+1G>T) present at ~23% variant allele frequency.
137 *TULP3* variants have not been associated with human disease according to OMIM, and
138 the c.253+1G>T variant does not show constraint for loss-of-function (LoF) variation
139 according to gnomAD (pLI=0), suggesting the splice site variant is not pathogenic. The
140 second variant identified was a *de novo* missense change in *AUTS2*
141 (NM_015570.3:c.1600A>C, p.(Thr534Pro)). This *AUTS2* variant is predicted to be
142 damaging by 16/25 *in silico* tools according to VarSome²⁷. Sanger sequencing of the
143 family trio confirmed its *de novo* status (Fig.1d). Although the vast majority of *AUTS2*
144 variants reported as pathogenic or likely pathogenic to the ClinVar database are
145 predicted to cause loss-of-function changes, five distinct missense variants (including
146 c.1600A>C identified in our patient) have been reported within amino acid residues 529-

147 535 (Fig. 1e). Sequence alignment of vertebrate amino acid sequences within the H1
148 region show that this portion of *AUTS2* is significantly conserved, suggesting functional
149 importance (Fig. 1f). Since few missense variants in *AUTS2* have been reported to
150 cause disease and given its expanding role in a range of neurological disorders, we
151 sought to investigate the underlying pathogenic mechanism of this p.Thr534Pro variant.

152

153 **Expression of *AUTS2* in excitatory neurons and progenitor cell types.**

154 To investigate which cell types may be affected by the *AUTS2*^{T534P} variant during
155 corticogenesis, we analyzed a published scRNA-seq CO and fetal brain dataset to
156 evaluate *AUTS2* expression at cell-type specific resolution¹⁹. These data indicate
157 *AUTS2* is expressed in a diversity of cell populations within the developing fetal brain
158 and COs with notable expression in excitatory neurons, radial glia, and intermediate
159 progenitors (Supplementary Fig. 1). Given the expression of *AUTS2* in these progenitor
160 cell types and the highly dynamic developmental program of NPC proliferation and
161 differentiation during corticogenesis, we sought to investigate its pathophysiology in
162 COs, which are an emerging model system that recapitulate morphological and early
163 neurodevelopmental features of the human brain.

164

165 ***AUTS2* patient COs exhibit patient-specific microcephaly and show proliferative 166 deficits in NPCs.**

167 To investigate the functional role of the *AUTS2*^{T534P} variant during human cortical
168 development, we reprogrammed peripheral blood monocytes from the *AUTS2*^{T534P}
169 patient and her parent as a control into human induced pluripotent stem cells (hiPSCs)
170 using Sendai virus-based delivery of Yamanaka transcription factors (Supplementary
171 Fig. 2). hiPSC colonies emerged within seven days post-infection showing tight cell
172 junctions, distinct cell borders, and alkaline phosphatase activity, which are
173 characteristic features of human pluripotent stem cells (Supplementary Fig. 2a,b). We
174 then evaluated the chromosomal integrity and pluripotency of the hiPSCs by
175 karyotyping (Supplementary Fig. 2c) and immunohistochemical analysis of key
176 pluripotency markers, including OCT3/4, SSEA4, NANOG and LIN28 (Supplementary
177 Fig. 2d). Additionally, we confirmed the heterozygous *AUTS2*^{T534P} variant was present in

178 the *AUTS2*^{T534P} patient line as demonstrated by Sanger sequencing (Fig. 1d). We then
179 used these hiPSC lines to generate three-dimensional COs with our undirected
180 differentiation protocol²⁸. Our overall approach for modeling the *AUTS2*^{T534P} variant in
181 COs is summarized in Figure 2a.

182 To investigate whether proband COs modeled the patient's microcephaly, we
183 differentiated proband and parental control hiPSCs into COs and performed a rigorous
184 growth trajectory analysis of COs within a dynamic neurodevelopmental time window of
185 NPC proliferation and differentiation (Fig. 1b-d). Proband and parental control COs were
186 indistinguishable by size or gross morphology until day 20 of culture, when proband
187 COs showed a statistically significant reduction in overall growth compared to the
188 parental control from day 20 (Fig. 1d). This trend persisted over time (day 20 median
189 cross-sectional area of proband COs was 0.71mm² compared to 1.41mm² in parental
190 control COs) (Fig. 2b-d). By day 28, the median cross-sectional area of proband COs
191 was 1.52mm² in proband COs compared to 2.56mm² in parental control COs
192 (coefficient of variation (CV)=49.01% in proband COs and 44.2% in parental control
193 COs). This trend was also observed across multiple cohorts (n=4), suggesting that the
194 proband COs recapitulate morphological features of the patient's microcephaly.

195 We then tested whether proliferative deficits in NPCs within ventricular-like
196 zones (e.g. neural rosettes) underly the growth deficits observed in proband COs. To
197 perform this analysis, we pulse-labeled proliferating cells in proband and control COs
198 with EdU²⁹, and performed a quantitative imaging analysis for the M-phase specific
199 marker, phospho-histone H3+ (pHH3) (see Supplementary Table 2 for all antibodies
200 utilized in this study), and EdU+ cells within neural rosettes. Our analysis revealed a
201 statistically significant reduction in the number of EdU+ and pHH3+ NPCs in proband
202 COs compared to the parental control (Fig. 2e-h). These data suggest proband NPCs
203 have deficits in cell cycle control, which may underlie the reduced growth properties of
204 proband COs.

205

206 **Proband COs exhibit increased asymmetric cellular divisions and ciliary defects**

207 Since cell cycle control and cellular division is tightly coupled within the VZ during
208 human corticogenesis, we investigated the dividing properties of apical progenitors

209 along VZ-like zones in proband COs. During early human brain development, NPCs
210 self-renew through symmetrical divisions along the ventricular surface to sufficiently
211 expand the pool of NPCs allowing for subsequent neurogenesis³⁰⁻³². After this rapid
212 symmetrical expansion of NPCs, they undergo a gradual shift towards dividing
213 asymmetrically to form a daughter NPC and either an intermediate progenitor cell (IPC)
214 or a neuron. Compared to rodent brain development, human brains undergo more
215 extensive symmetrical divisions of apical progenitors and increased basal progenitor
216 proliferation within the oSVZ resulting in a larger frontal cortex³⁰⁻³², a key difference
217 which may explain why mutations causing microcephaly in humans are not adequately
218 modeled in the mouse. Several studies have suggested primary microcephaly results in
219 the loss of cortical expansion caused by premature neuronal differentiation due to the
220 depletion of dividing progenitors^{21,22,33}. This process occurs when progenitors
221 prematurely undergo asymmetric divisions to generate neurons instead of additional
222 progenitors at an early stage of neurodevelopment. (Fig. 3a).

223 To test whether a similar mechanism of premature asymmetric divisions occurred
224 in proband NPCs, we measured the division angles of SOX2+ apical progenitors at the
225 VZ within our COs using the mitotic spindle marker TPX2 and apical zone marker ZO1
226 (Fig. 3b-c). Approximately one third of divisions within parental control COs were
227 asymmetric (vertical: 18%, oblique: 18%, horizontal: 64%; n=95 cells) whereas nearly
228 two-thirds of divisions in the proband *AUTS2*^{T534P} COs were asymmetric (vertical: 31%,
229 oblique: 34%, horizontal: 35%; n=126 cells). This approximate two-fold increase in
230 asymmetric divisions within proband COs indicates progenitors may be undergoing
231 premature neuronal differentiation. Taken together, the overall decrease in proliferation
232 and increase in neurogenic, asymmetrical divisions within proband COs suggests that
233 the *AUTS2*^{T534P} variant adversely affects NPC cell cycle dynamics and/or cell fate
234 determination.

235 We next analyzed the primary cilium within neural rosettes as this structure is
236 critical in establishing NPC columnar organization within the VZ and is directly involved
237 in cell cycle kinetics of various cell types, including NPCs. Several microcephalic
238 phenotypes have been linked to disruptions in primary cilium dynamics^{22,34-36}. We found
239 VZ-like structures within proband COs that lacked NPC columnar organization and

240 uniform polarity. Specifically, they exhibited disrupted microtubule networks within
241 rosettes, as shown by their irregular acetylated tubulin immunoreactivity (Fig. 3g,h,i)
242 compared to controls (Fig. 3e-f, i). Additionally, we observed a statistically significant
243 reduction in the length of proband ARLB13B+ cilia compared to controls (Fig. 3k).
244 Collectively, these results suggest the proband COs exhibit deficits in ciliary properties
245 and organization with a concomitant loss of NPC polarity within CO rosettes. Since
246 primary cilium formation and resorption is imperative to the progression of the cell cycle,
247 the loss of NPC polarity in proband COs provides further evidence that the *AUTS2*^{T534P}
248 variant impairs their proliferative capacity.

249 Given the established role of *AUTS2* in neuronal migration⁶, we then evaluated
250 whether there were any overt abnormalities in progenitor cell migration by analyzing the
251 distribution of TBR2+ intermediate progenitor cells (IPCs) surrounding neural rosettes in
252 proband COs. We did not observe any marked differences in the distribution of TBR2+
253 IPCs demarcating neural rosettes within both proband and control COs (Supplementary
254 Fig. 3a). Further, no IPCs were detected within proband or control rosettes as expected,
255 suggesting the *AUTS2*^{T534P} variant may not substantially affect progenitor migration. To
256 investigate *AUTS2* expression in proband COs, we observed both cytoplasmic and
257 nuclear expression of *AUTS2* in NPCs, similar to the parental control, and verified
258 *AUTS2* staining specificity using a blocking peptide directed against the *AUTS2*
259 antibody utilized. These data suggest the *AUTS2*^{T534P} variant does not alter normal
260 *AUTS2* expression patterns (Supplementary Fig. 3b). We also observed that a subset of
261 IPCs were both *AUTS2*+ and TBR2+ in both proband and control COs, which is
262 consistent with our synthetic scRNA-seq analysis (Supplementary Fig. 1).

263
264 **Growth area and NPC proliferative deficits in proband COs are rescued by gene**
265 **correction.**

266 To investigate whether the phenotypes we observed in proband COs were caused by
267 the *AUTS2*^{T534P} variant, we gene corrected this alteration to the wild-type sequence using
268 CRISPR-Cas9 homology directed repair (Fig. 4a). A small guide (sg) RNA (20 base pairs)
269 targeting the *AUTS2* variant region was designed that contained <2 base pair matches to other
270 sequences in the genome to ensure precise gene targeting. Additionally, a silent edit was

271 inserted in the single-stranded oligo donor (ssODN) sequence to disrupt repeated sgRNA
272 binding and subsequent re-cutting by Cas9 after successful editing (Fig. 4b). sgRNA and
273 ssODN sequences are provided in Supplementary Table 3. Synthego's Inference of CRISPR
274 Edits (ICE) software tool was then used to measure the frequency of successful gene editing.
275 We then generated single iPSC clones, screened ~100 of them using Sanger sequencing, and
276 confirmed three clones showed both successful gene correction (c.1600C>A) and introduction
277 of the silent gene edit (c.1608G>A). Next, we verified pluripotency markers using
278 immunofluorescence analysis and chromosomal stability using karyotype analysis in the GC
279 hiPSC line prior to generating COs (Supplementary Fig. 2b-d).

280 We then generated COs using an optimized protocol to enhance organoid
281 reproducibility in our cultures^{37,38} and to test whether GC of the *AUTS2* variant rescued the
282 microcephalic phenotype we observed in proband COs (Fig. 4c-g). This protocol obviates the
283 requirement to encapsulate neuroepithelial bodies and generates morphologically reproducible
284 and robust COs compared to prior protocols^{37,38}. Consistent with our previous studies, proband
285 COs generated by this method showed a reduction in growth compared to parental control
286 COs (day 30 median cross-sectional area of proband COs was 1.44 mm² compared to 2.43
287 mm² in parental control COs) (Fig. 4h,i,q). In contrast, our GC COs showed a statistically
288 significant increase in cross sectional area compared to proband COs, suggesting phenotypic
289 rescue and that the *AUTS2*^{T534P} variant contributes to organoid growth deficits (day 30 median
290 cross-sectional area of GC control COs was 1.68 mm², 75th percentile cross-sectional areas
291 were 1.55 mm² in proband COs compared to 2.11 mm² in GC control COs and 2.81 mm² in
292 parental control COs (Fig. 4i,j,q). However, no statistically significant difference in cross-
293 sectional area was observed between the parental control and GC control COs. This finding
294 may suggest the gene correction results in a partial rescue and/or highlights the variability in
295 growth properties of COs arising from intrinsic differences between hiPSC lines (Fig. 4r). The
296 latter scenario underscores the value of performing these types of analyses with a GC hiPSC
297 line. Our optimized CO generation protocol resulted in a significant reduction of the CV in CO
298 area measurements across groups compared to our earlier CO area growth analysis
299 (CV=12.78% in proband COs, 26.86% in parental control COs, and 29.77% in GC control
300 COs), which suggests this improved CO generation protocol lowers organoid-to-organoid
301 variability.

302 Next, we tested whether NPC proliferative deficits in proband COs were rescued by the
303 *AUTS2* variant gene correction. Similar to our prior experiment, we pulse-labeled proliferating
304 cells in COs with EdU and then performed a quantitative imaging analysis for pHH3+ and
305 EdU+ cells within neural rosettes across all organoid groups (Fig. 4k-p). Although an increased
306 trend in the number of EdU+ was observed in the GC control compared to proband COs, this
307 increase did not reach statistical significance (Fig. 4r). However, a statistically significant
308 increase in the number of pHH3+ NPCs was observed in the GC control compared to proband
309 NPCs (Fig. 4s). In addition, no significant difference was observed between the parental
310 control and the GC control, suggesting phenotypic rescue, and thus providing further evidence
311 that the *AUTS2*^{T534P} variant contributes to deficits in NPC proliferation (Fig. 4s).

312
313 **Single-cell RNA sequencing reveals a susceptible population of NPCs in proband COs**
314 **that is rescued by gene correction.**

315 To determine cell-type specific transcriptomic signatures underlying the proband COs
316 microcephalic phenotype, we performed scRNA-seq analysis in day 30 proband COs (n=8
317 organoids pooled per group; Fig. 5). We performed unsupervised clustering on gene
318 expression profiles from an integrated dataset of 35,633 cells and identified ten composite
319 clusters using canonical marker genes (Supplementary Fig. 4). Since the scope of our study
320 primarily concerned NPCs and differentiated immature neurons, we subclustered them for
321 further analysis. This sub-clustering resulted in five cell types from an integrated dataset of
322 17,752 cells, which were comprised of *EOMES*+ intermediate progenitor cells (IPCs),
323 *STMN2*+/*GAP43*+/*TBR1*+ immature neurons, and three classes of *SOX2*+ neural progenitor
324 cells (NPCs) (Fig. 5a,b). Upon initial analysis, we observed a drastic reduction in the relative
325 proportion of Type 2 NPCs in proband COs compared to both controls (Fig. 5c-h). Strikingly,
326 Type 2 NPCs constituted approximately 22% of cells within parental control COs, but only
327 0.25% in proband COs. This underrepresented NPC population was significantly rescued in
328 GC control COs showing a 22-fold increase of Type 2 NPCs (5.5% of total) compared to
329 proband COs, suggesting the reduction of this cell type is related to the *AUTS2*^{T534P} variant.
330 We also observed a two-fold increase in the percentage of immature neurons in proband COs
331 (29%) compared to parental control COs (14%), which supports our earlier results showing
332 increased asymmetrical divisions and subsequent premature neuronal differentiation in

333 proband COs. The GC control also showed a decrease in the percentage of immature neurons
334 compared to proband COs (from 29% in proband COs to 23% in GC control COs), suggesting
335 that gene correction of the *AUTS2* variant partially restores the proper timing of neurogenesis
336 in COs. We also noted a nearly two-fold increase in the percentage of IPCs in proband COs,
337 which constitute 7% of all subclustered cells but only 3-4% in control COs. Analysis of *AUTS2*
338 expression in our sc-RNA seq data showed similar levels across both proband and control
339 groups in NPCs and in immature neurons, suggesting the *AUTS2*^{T534P} variant does not affect
340 mRNA stability (Supplementary Fig. 5).

341 Next, we investigated gene expression signatures enriched in Type 1 and Type 3 NPCs.
342 Type 1 NPCs were enriched for G2/M phase gene expression signatures such as *MKI67* and
343 *TOP2A* and Type 3 NPCs were enriched for *FABP7* and *SOX9*, transcription factors which are
344 critical for NPC proliferation and promote neuronal and glial fate specification³⁹⁻⁴² (Fig. 5b,
345 Supplementary Fig. 4). Type 1 NPCs were comprised of similar percentages within proband
346 (24.8%) and parental control COs (26.7%) and were elevated approximately by 10% in GC
347 control COs. Type 3 NPCs showed an approximate 5% increase in proband COs compared to
348 both control COs. The significance of these differences is unknown and warrants future
349 investigation.

350 To determine specific biological processes and molecular functions that characterize
351 Type 2 NPCs, we performed a gene ontology analysis from the top enriched gene expression
352 signatures identified in Type 2 NPCs (Fig. 5i). Type 2 NPCs were enriched for the GO terms:
353 anterior/posterior pattern specification (GO:0009952), ribosome assembly (GO:0042255),
354 G1/S transition of mitotic cell cycle (GO:0000082), protein-DNA complex assembly
355 (GO:0071824), and others (Fig. 5i). Further analysis of gene signatures identified within the
356 anterior/posterior pattern specification gene ontology revealed genes associated with midbrain
357 and hindbrain specification (e.g. *OLIG3*, *HOXA2*) (Supplementary Fig. 6). Thus, *AUTS2* may
358 play a critical role in specifying these cells fates and may explain why *AUTS2* syndrome
359 patients display cerebellar hypoplasia. Additionally, the Type 2 NPCs were enriched for
360 *CCND1*, *EIF4EBP1*, *CDK6*, *CCND2*, and other gene expression signatures, all of which
361 contribute to the G1-S transition phase of the cell cycle (Fig. 5j). Expression analysis of these
362 cell cycle genes showed significant reductions in proband COs, which were restored in GC
363 COs (Fig. 5k). Collectively, these findings suggest that the *AUTS2*^{T524P} variant in proband COs

364 leads to a selective loss of proliferating progenitors, which is consistent with a reduced
365 percentage of EdU+ and pHH3+ progenitors and consequential microcephalic phenotype in
366 proband COs compared to controls (Fig. 2e-h,4h-t). These results suggest AUTS2 plays an
367 important role in the progression of the cell cycle within NPCs, which is critical for proper timing
368 of human corticogenesis.

369 **Proband NPCs show dysregulated gene expression associated with WNT- β -catenin**
370 **signaling, chromatin modification, and gliogenesis.**

371 To further investigate underlying molecular mechanisms affecting NPC proliferative
372 deficits in *AUTS2* patient COs, we performed gene ontology analyses from genes identified
373 within the Type 1 and 3 NPC clusters that were differentially expressed in comparison to both
374 parental and GC control COs. In Type 1 NPC, we observed differentially expressed genes
375 (DEGs) that were enriched for the GO terms: brain development (GO:0007420), CNS neuron
376 differentiation (GO:0021953), WNT signaling pathway (GO:0016055), chromatin silencing
377 (GO:0006342), and others (Fig. 6a). Of note, the chromatin modifying gene, *HMGA1*, showed
378 reduced expression in proband COs (Fig. 6b), which has been shown to play an important role
379 in controlling the neurogenic potential of NPCs and the developmental timing of
380 gliogenesis^{43,44}. Other chromatin modifying genes, *HIST1H2AG* and *KCNQ1OT1*, were also
381 dysregulated. Our analysis also identified increased expression levels of *MAP2*, which is
382 consistent with our earlier finding that proband NPCs are undergoing premature neuronal
383 differentiation. *NFIB* and *FGFR3* expression levels were also induced in proband Type 1
384 NPCs, suggesting these progenitors show a propensity towards glial cell differentiation.
385 Interestingly, we observed increased expression of the homeobox transcription factor, *TSHZ2*,
386 and the neural cell adhesion gene, *CNTNAP2*, both of which have been previously identified
387 as *AUTS2* target genes in mouse studies⁴⁵ (Fig. 6b). We then focused our analysis on those
388 DEGs associated with WNT signaling as numerous studies have underscored its critical role in
389 regulating NPC proliferation and differentiation within the ventricular zone⁴⁶⁻⁴⁸. *CTNNB1*, which
390 is the major signal transducer of WNT signaling, was significantly reduced in proband COs
391 within both Type 1 and 3 NPCs and immature neurons. We also observed alterations in the
392 expression of multiple genes in proband COs compared to control COs, which function in
393 regulating WNT signaling activity such as *RSPO3*, *SFRP2*, *GPC4*, and *SULF2* (Fig. 6c,d).
394 Cyclin D1 (encoded by the *CCND1* gene) is a well-characterized target for WNT- β -catenin

395 signaling, which promotes G1/S phase transition of the cell cycle^{49,50}, was reduced in proband
396 NPCs compared to controls (Fig. 5k). Collectively, our data suggests that proband NPCs show
397 deficits in WNT- β -catenin signaling, which may underly their proliferative deficits and
398 impairment to transition through the G1/S phase of the cell cycle.

399 We then performed the same type of GO analysis for Type 3 NPCs and observed DEGs
400 that were enriched for the GO terms: brain development (GO:0007420), WNT signaling
401 pathway (GO:0016055), regulation of glial cell differentiation (GO:0045685), cell division
402 (GO:0051301), and others (Fig. 6e). Similar to Type 1 NPCs, Type 3 NPCs showed reduced
403 expression of *HMGA1* and dysregulated expression of the WNT signaling regulators, *RSPO3*,
404 *SFRP2*, and *ZIC1*. In addition, we observed dysregulated expression of the centromere
405 binding genes, *CENPF* and *CENPW*, which may contribute to the polarity and mitotic deficits in
406 proband NPCs compared to controls. Increased expression of the *HES1* and *ID3* genes were
407 also observed in proband NPCs. Previous studies have suggested that HES1 and ID3 promote
408 the specification of neural precursors towards an astrocyte fate^{51,52}, which suggests proband
409 NPCs may have an altered propensity to differentiate into glial identities.

410 Next, we examined the DEGs identified in immature neurons from our sc-RNA seq data.
411 Mouse studies have underscored a critical role for *AUTS2* in controlling neuronal gene
412 expression and specifying neuronal cell fates, however few studies have examined the role of
413 *AUTS2* in human corticogenesis and its biological link to intellectual disability observed in
414 *AUTS2* syndrome patients. Similar as described above, we performed a GO analysis on
415 DEGs from immature neurons and identified the following enriched biological processes:
416 synapse maturation (GO:0060074), cholesterol biosynthesis (R-HSA-191273), glial cell
417 differentiation (GO:0010001), and cytoskeleton organization (GO:0045104), among others
418 (Fig. 6g). We observed dysregulated expression in the synaptic maturation genes, *NEFM*,
419 *RELN*, *NRXN1*, and reduced expression of genes controlling cholesterol metabolism such as
420 *ACAT2* and *HMGCS1* (Fig. 6h). Other altered gene expression levels were observed in genes
421 regulating cytoskeletal organization: *SMC1A* and *NEFM*; and neurite morphogenesis: *DCC*
422 and *MDK*. Interestingly, *Nrxn1* and *Reln* were previously identified as *AUTS2* target genes in
423 mouse studies using ChIP Seq⁴⁵. In addition, *NRXN1*, *DCC*, *RELN*, and *SMC1A* have all been
424 implicated in ASD and ID and are designated Simons Foundation Autism Research Initiative
425 (SFARI) genes⁵³⁻⁵⁷. Further studies are warranted to understand the impact of these altered

426 gene expression patterns on synaptic maturation and activity during neurodevelopment using
427 *in vitro* and *in vivo* models of *AUTS2* deficiency and whether they are linked to cognitive
428 deficits in ASD/ID patients.

429

430

431 **DISCUSSION**

432 This study provides novel molecular insights into *AUTS2* function within NPCs,
433 which may underly the neurological manifestations of microcephaly and syndromic
434 intellectual disability observed in *AUTS2* syndrome patients. Previous animal studies
435 have identified a role for *AUTS2* in transcriptional activation, RNA metabolism, and
436 cytoskeletal regulation in excitatory neurons. However, these animal models of *AUTS2*
437 deficiency do not develop reductions in cortical volume (i.e. microcephaly) and therefore
438 may not adequately recapitulate disease mechanisms underlying *AUTS2* syndrome
439 within the cerebral cortex.

440 Here we present a patient with a *de novo* pathogenic *AUTS2*^{T534P} missense
441 variant who presents with *AUTS2* syndrome. We established a CO model of this patient
442 to investigate the human-specific pathogenesis of *AUTS2*^{T543P} in the early developing
443 brain. Our results indicate that *AUTS2* deficiency leads to a microcephalic phenotype,
444 which dysregulates cell cycle dynamics within NPCs, leading to a subsequent reduction
445 in proliferation, ciliary defects and the selective loss of progenitors enriched for gene
446 expression associated with G1/S cell cycle transition. Further, scRNA-seq analysis
447 revealed deficits in WNT- β Catenin signaling in NPCs, which may underly their
448 proliferative deficits. Multiple studies have underscored the critical role of β -Catenin
449 within NPCs during neurodevelopment. For example, conditional deletion of β -Catenin
450 in mouse cortical NPCs led to reduced cell proliferation and disruptions in the
451 organization of the neuroepithelium⁴⁷. Conversely, overexpression of a stabilized form
452 of β -Catenin in NPCs increased cell proliferation⁴⁶. Additionally, focal depletion of β -
453 Catenin within NPCs of the mouse ventricular zone caused premature cell cycle exit
454 and neuronal differentiation⁴⁸. However, it is unclear how *AUTS2* deficiency is related to
455 deficits in WNT- β Catenin signaling, although a few studies have suggested WNT- β
456 Catenin signaling and *AUTS2* share common downstream targets. For example, the

457 WNT target gene, *Cachd1*, was recently identified as an RNA transcript that can be
458 bound and regulated by AUTS2¹⁴. Other shared AUTS2 targets identified using CHIP
459 Seq⁴⁵ and targets of Wnt signaling using RNAseq⁵⁸ include *Fzd1* and *Nfia*. It is also
460 plausible that altered expression of chromatin modifying genes observed in proband
461 NPCs may dysregulate downstream WNT target gene expression. Interestingly,
462 *CTNNB1* gene mutations have been associated with dysmorphic features,
463 microcephaly, and intellectual disability in patients^{59,60}, clinical symptoms all of which
464 have been observed in AUTS2 syndrome patients. Further investigation is required to
465 determine whether overexpression of *CTNNB1* in *AUTS2*^{T543P} COs can rescue NPC
466 proliferative deficits.

467 More recent work by Liu *et al* demonstrated the HX domains of AUTS2, including
468 the HQ-rich domain within exon 9, are critical for the previously characterized AUTS2-
469 P300 complex⁶¹. Variants that fall within this HQ-rich domain are associated with
470 neurological symptoms such as microcephaly and intellectual disability—a strikingly
471 similar clinical presentation to Rubinstein-Taybi syndrome, which is caused by
472 pathogenic variants in *CREBBP/P300*. In this study, the *AUTS2*^{T534P} variant is deficient
473 in recruiting P300 to the PRC1.5-AUTS2 complex, leading to transcriptional
474 dysregulation of downstream target genes. Although this work provides important
475 insight to the mechanism by which the *AUTS2*^{T534P} variant alters PRC1.5-AUTS2
476 activity, our study provides novel molecular insights into how this variant leads to
477 pathogenesis in the developing human brain.

478 One of the challenges associated with CO modeling is variability associated with
479 utilizing different hiPSC lines and organoid-to-organoid variability present within a
480 particular experimental batch. We addressed these challenges by 1) adapting a
481 modified CO protocol to enhance organoid reproducibility, and 2) generating an
482 isogenic, gene-corrected hiPSC line. By gene correcting this variant in proband hiPSCs,
483 we determined the proliferative and molecular deficits observed in proband NPCs were
484 directly linked to the *AUTS2* variant. In GC COs, we observed a statistically significant
485 rescue of overall growth compared to proband COs, although overall growth of GC COs
486 did not match that of parental control COs. However, at the molecular level, GC COs
487 showed a statistically significant rescue in the percentage of proliferating pHH3+ NPCs

488 compared to proband COs. Additionally, sc-RNAseq analysis of GC COs showed a
489 rescue of molecular alterations underlying proliferative deficits within proband NPCs.

490 Our sc-RNAseq analysis also uncovered an NPC population that was strikingly
491 underrepresented in proband COs. GO analysis revealed these Type 2 NPCs were
492 enriched in gene expression signatures associated with G1/S cell cycle transition in
493 addition to marker genes associated with midbrain and hindbrain specification. The loss
494 of these cell fates in combination with proliferative deficits observed in proband NPCs,
495 most likely contributes to the microcephalic phenotype observed in proband COs.
496 Interestingly, the *AUTS2* syndrome patient described here also displays cerebellar
497 hypoplasia (Fig. 1b), which may be the result of deficits in hindbrain fate specification.
498 Investigation of the *AUTS2*^{T534P} variant using cerebellar organoids would provide
499 greater mechanistic insight into *AUTS2* function during cerebellum development.

500 Future studies are required to expand upon our findings and evaluate the
501 mechanisms by which *AUTS2* controls cell cycle progression in early NPCs.
502 Additionally, other disease-causing variants, such as those found within the mutation
503 hotspot within the ninth exon of *AUTS2*, warrant further investigation. Since *AUTS2* is a
504 master neuronal transcriptional activator, microcephaly in *AUTS2* syndrome patients
505 may arise from dysregulation of multiple downstream target genes. Thus, future studies
506 are required to elucidate how transcriptional activation of *AUTS2* variants is altered in
507 NPCs and differentiated neuronal progeny. Our results show a critical role for *AUTS2* in
508 NPC proliferation and neuronal specification during early human cortical development,
509 deficits of which may contribute to the clinical manifestations observed in *AUTS2*
510 syndrome patients. In sum, this study highlights the value of COs to advance our
511 understanding of mechanisms underlying *AUTS2* syndrome with the ultimate goal of
512 developing therapeutic strategies for patients.

513

514

515 **MATERIALS & METHODS**

516

517 **Subjects.** The proband and both of her parents were enrolled as part of an Institutional
518 Review Board (IRB) approved study (IRB:11-00215: Rare Diseases/Genome
519 Sequencing) within the Steve and Cindy Rasmussen Institute for Genomic Medicine at
520 Nationwide Children's Hospital. Informed consent was provided for all study participants
521 to partake in this research and to have this work published. Genomic analysis was
522 performed on DNA isolated from either peripheral blood or saliva samples.

523

524 **Whole genome sequencing and analysis.** Whole-genome sequencing was performed
525 for all three members using an Illumina HiSeq4000 instrument according to
526 manufacturer protocols. Reads were mapped to the GRCh37 reference sequence, and
527 secondary data analysis was performed using Churchill (Kelly et al., 2015), which
528 implements the GATK "best practices" workflow for alignment, variant discovery and
529 genotyping. Variants were called using GATK 4.0.5.1, and the resulting VCF file was
530 annotated with genes, transcripts, function classes, damaging scores, and population
531 allele frequencies using an in-house pipeline built around the SNPeff annotation tool.⁶²
532 Our general approach to variant annotation and prioritization has been previously
533 described.⁶³ After removing common variants (MAF>0.01 in the gnomAD v.2.1.1
534 database), we selected for further analysis all splice site, frameshift, and nonsense
535 variants, as well as missense variants predicted to be damaging by SIFT (score<0.05),
536 Polyphen (score>0.453), GERP (score>2.0), or CADD (Phred score>15). Because of
537 the severe presentation and lack of a significant family history, we prioritized candidate
538 de novo mutations consistent with dominant inheritance, but recessive and X-linked
539 models were also considered.

540

541 **CO culture.** *iPSC cell line generation and quality control testing:* Peripheral blood
542 mononuclear cells (PBMCs) were reprogrammed to human induced pluripotent stem
543 cells (hiPSCs) using the CytoTune-iPS 2.0 Sendai Reprogramming Kit (ThermoFisher)
544 according to manufacturer's instructions. All hiPSC lines used in this assay were

545 rigorously tested for pluripotency markers, tested negative for mycoplasma, and
546 underwent short tandem repeat (STR) profiling analysis (LabCorp) to authenticate purity
547 of cell lines. In addition, all hiPSC lines were tested for live alkaline phosphatase activity
548 using the Alkaline Phosphatase Live Stain kit (ThermoFisher) according to
549 manufacturer's instructions. *iPSC culture maintenance*: All lines were maintained under
550 feeder-free and defined, serum free medium conditions. iPSCs were cultured in either
551 mTeSR (StemCell Technologies) or Essential 8™ Medium (ThermoFisher) and
552 passaged on vitronectin-coated tissue culture plates using standard methods. *CO*
553 *generation*: All media formulations for CO generation are described in Supplementary
554 Table 4. The initial cohorts of whole brain CO used in Figures 2 and 3 were generated
555 according to our previously described protocol²⁸. CO culture media were exchanged
556 every third day. An adapted whole brain CO generation protocol was used for
557 subsequent analyses in Figures 4 and 5 optimized to increase CO reproducibility. In this
558 CO protocol, iPSC lines were thawed from cryopreservation and passaged a minimum
559 of one time and maintained in culture for at least seven days. iPSCs at 65-85%
560 confluency were pre-treated with 5µM Y-27632 ROCK Inhibitor for 1 hour and then
561 processed into single cells with TrypLE dissociation reagent (ThermoFisher). Cells were
562 then resuspended in iPSC media supplemented with 5µM ROCK inhibitor at a
563 concentration of 40 cells/µl. Then, 100µl of the suspension was transferred into each
564 well (4,000 cells/well) of a non-tissue culture u-bottom 96-well plate. The plates were
565 then balanced and spun down at 400g for 4 minutes. Although the embryoid bodies
566 (EBs) began to noticeably form within a few hours of seeding, plates were left
567 undisturbed for 72 hours for optimal EB formation. After EB formed, media and
568 unincorporated cells were aspirated from each well and replaced with 150µl of fresh
569 Neural Induction Medium (NIM). The NIM was replaced every other day until Day 10.
570 On Day 10, EBs were transferred to a larger plate format (10cm² untreated dishes) with
571 Cerebral Organoid Expansion Medium (COEM) + 2% Matrigel and placed on an orbital
572 shaker. Then, 72 hours later, the COEM was removed and replaced with Cerebral
573 Organoid Growth & Differentiation Medium (COGDM) + 1% Matrigel. Organoids
574 received fresh COGDM three times per week for the remainder of their time in culture.
575 All media formulations were prepared according to our previous studies²⁸.

576 **AUTS2 exon 9 PCR amplification and Sanger DNA sequencing.** Polymerase chain
577 reaction (PCR) was performed using the JumpStart REDTaq ReadyMix Reaction Mix
578 (Sigma) with the following experimental conditions: 200ng of genomic DNA, 25µM of
579 primers (*AUTS2* Exon9-Forward primer: 5'-TCTTGCGACAGGAACTGAACA-3', *AUTS2*
580 Exon9-Reverse primer: 5'-GTGCTCTACTTATCCTCACATTTTGC-3'), and the
581 JumpStart REDTaq ReadyMix. PCR cycling parameters were the following: initial
582 denaturation 2 minutes at 94° followed by 35 cycles at 94° for thirty seconds, thirty
583 seconds at 60°, one minute at 72°, and a final extension of five minutes at 72°. Agarose
584 gel electrophoresis was used to visualize PCR products and then were excised and
585 extracted using the QIAquick Gel Extraction Kit (Qiagen). Purified PCR products were
586 then processed for Sanger DNA sequencing (Eurofins) using both *AUTS2* Exon9F and
587 *AUTS2* Exon9R primers.

588
589 **CRISPR/Cas9 *AUTS2* variant gene correction and iPSC clone screening.** The
590 patient hiPSC line harboring the *AUTS2*^{T534P} variant was gene corrected in collaboration
591 with Synthego with the specific gene correction and silent edit: *AUTS2*^{P534T} (c.1600C>A,
592 c.1608G>A) (Fig. 4b). A small guide (sg) RNA (TGTGCTGGTGCGTGTGCTGG) was
593 designed that contained <2 base pair matches to other sequences in the genome to
594 ensure precise gene targeting. The sgRNA was then complexed with Cas9 to generate
595 a ribonucleoprotein complex and together with the single-stranded oligo DNA donor
596 (Supplementary Table 3) were nucleofected into *AUTS2*^{T534P} hiPSCs. Synthego's
597 Inference of CRISPR Edits (ICE) software tool was then used to measure the frequency
598 of successful gene editing. iPSCs were then dissociated with TrypLE Express
599 (Thermofisher) and seeded at 0.5 cells/well into a 96 well dish and allowed to expand to
600 confluency. Genomic DNAs from single iPSC clones were then isolated and screened
601 using Sanger sequencing to confirm successful gene correction and introduction of the
602 silent gene edit.

603
604 **Conservation analysis.** The full length *AUTS2* isoform sequence (*AUTS*-isoform 1 on
605 UniProtKB) were selected from UniProtKB database. UniProtKB's in-built ClustalW
606 (Clustal Omega) alignment tool was used to perform sequence alignment. The following

607 default alignment parameters were used- default transition matrix Gonnet, gap penalty
608 of 6 bits, gap extension of 1 bit. The default alignment algorithm HHAAlign (Soding J,
609 2005.) was used to perform sequence alignment.

610
611 **Collation of *AUTS2* exon 9 variants.** Exon information of *Homo sapiens AUTS2* full
612 length isoform (Ensembl ID- ENST00000342771.10) was determined based on UCSC
613 Genome browser annotation. Based on this exon 9 mapping, all unique *AUTS2* exon 9
614 variants on ClinVar, LOVD (Leiden Open Variant Database) and HGMD were collected
615 and tabulated.

616
617 **Immunohistochemistry.** Fixation: Cerebral organoids (COs) were fixed in 4%
618 Paraformaldehyde (PFA, Electron Microscopy Sciences, 15713)/DPBS (Gibco, 14190-
619 144) at 4°C overnight. The next day, COs were placed on a shaker in PFA solution at
620 RT for 10-15 minutes to finalize fixation. Once entirely fixed, residual PFA was removed
621 with three DPBS washes. COs then underwent a sucrose gradient: first, COs were
622 equilibrated to 10% Sucrose (Sigma Life Sciences, S7903-250G)/1% Antibiotic-
623 Antimycotic (Gibco, 15240-062)/ DPBS solution overnight. Then, COs were transferred
624 to a 30% sucrose/1% Antibiotic-Antimycotic/DPBS solution to equilibrate overnight
625 again. Preparation for Cryosectioning: The COs and the 30% sucrose solution were
626 inverted into a petri dish and transferred to excess optimal cutting temperature (OCT)
627 solution (Sakura Finetek USA Inc, 4583) with a sterile, trimmed transfer pipet. Up to five
628 COs were placed quickly into the mold, minimally rearranged in a grid-like fashion, and
629 immediately frozen in a bath of dry ice pellets and methanol. The COs were stored at -
630 80°C until sectioned. Cryosectioning: The embedded tissue was removed from -80°C
631 and mounted on a cryostat chuck with dry ice. The mounted tissue was placed in the
632 cryostat (ThermoFisher, 957020) to equilibrate to -14°C for approximately one hour.
633 Then, the tissue was sectioned at 20µm directly onto positively charged glass slides
634 (Fisherbrand, 1255017) in the cryostat. The slides were stored at -30°C until further
635 processing. Staining: Slides containing sections were then thawed at room temperature
636 (RT) for at least twenty minutes, outlined with a hydrophobic maker (Life Technologies,
637 008899), and re-hydrated in PBS. Slides were then incubated with blocking solution

638 containing 0.1% Triton X-100/10% donkey serum/Tris Buffer Solution (TBS) for one
639 hour at room temperature. Slides were then incubated with primary solution (blocking
640 solution, antibodies per dilutions described in Supplementary Table 2) for 16-24 hours
641 at 4°C. Slides were then rinsed three times with TBS solution. Then, secondary solution
642 (blocking solution, species-appropriate secondary antibodies and DAPI) was added and
643 incubated for 2 hours at RT. Residual secondary antibodies were removed with three
644 TBS washes. Slides were then immediately cover-slipped with Fluoromount-G®
645 (SouthernBiotech, 0100-01). Imaging: Images were captured with confocal microscopy
646 on a scanning laser confocal microscope (Zeiss LSM 800).

647
648 **CO phenotype characterization.** Organoid area quantification: Organoid cross-
649 sectional areas were extracted from phase contrast images using FIJI and analyzed for
650 trends in GraphPad Prism X. Mitotic angle analysis: Angle calculations were determined
651 using fixed organoid slices stained with TPX2, ZO1, and DAPI to label spindle
652 microtubules during mitosis, the ventricular surface, and cell nuclei, respectively. First,
653 the ventricular surface was outlined using the Adobe Photoshop 2020 Curvature Pen
654 Tool with a solid line one pixel in width. Next, the Add Anchor Point Tool was used to
655 ensure the outline closely adhered to the border of the ventricular surface. ZO1 and
656 DAPI were used to describe the ventricular surface. Second, the line of cleavage was
657 similarly drawn between the TPX2 signals of cells caught in mitosis. Third, the line of
658 cleavage was copied and transposed to intersect the ventricular surface outline at its
659 closest point using the Path Selection Tool. Fourth, the outlined images were quantified
660 on ImageJ (FIJI) using the Angle tool to measure the angle of cleavage as defined by
661 the acute angle formed by the transposed line of cleavage and the intersecting portion
662 of the ventricular surface for each cell. Finally, each cell was given a division
663 classification of vertical, oblique, or horizontal according to its angle of division falling
664 between 0-30°, 30-60°, or 60-90°, respectively. EdU and pHH3 analysis: First, rosette
665 boundaries were drawn on a merged image of Edu, pHH3 and DAPI signal using the
666 Polygon Selection Tool in FIJI. Then, EdU+ and pHH3+ cells were then manually
667 quantified, and trends were analyzed in GraphPad Prism X. Cilia length and count
668 analyses: Tissue sections from the parental control and proband lines were stained with

669 ARL13B, SOX2 and DAPI according to our IHC protocol. The sections were then
670 surveyed to locate and collect z projection images of rosettes. The upper and lower
671 boundaries of the z projection were defined by ARL13B signal (i.e. appearance of cilia).
672 A maximum projection was then generated and used in subsequent analyses, where
673 cilia length and count as well as rosette area were determined using the ROI and
674 measurement tools in FIJI (ImageJ v.2.0.0-rc-69/1.52p). All statistical analyses were
675 performed using one-way ANOVA with Tukey's multiple comparisons test.

676

677 **Single-cell RNA sequencing sample processing.** Cerebral organoids were pooled in
678 groups of eight (per line) and prepared for single-cell RNA sequencing as previously
679 described²⁸. In brief, organoids were dissociated into a single cell suspension using a
680 gentleMACS Octo Dissociator (Miltenyi) with the manufacturer's "37 °C_ABDK_02"
681 program. Then, 2 mL solution of Accumax (Sigma, A7089) was transferred into a
682 gentleMACS C-tube (Miltenyi, 130-093-237), organoids were placed in this solution and
683 processed using an Octo-Dissociator instrument (Miltenyi) . After the program
684 completed, 10mL of DPBS + 0.04% BSA (Sigma, A9418) were added to each C-tube
685 and then sample solution was filtered through a 70µm strainer to remove undissociated
686 tissue and debris. Dissociated and strained cell mixtures were then centrifuged for two
687 minutes at 300g and resuspended in 1mL DPBS + 0.04% BSA. Additional cell filtration
688 steps was performed to remove fine cell debris using a 40 µm Flowmi® cell strainer
689 (Sigma, BAH136800040). We found repeating this filtration step twice yielded a cell
690 suspension devoid of cell debris for all lines. The concentration and viability of each
691 suspension was then manually determined using trypan blue staining and a
692 hemocytometer. Finally, samples were diluted to achieve a concentration of 1,000
693 cells/µL. Approximately 10,000 cells were used to generate single cell RNA-seq libraries
694 using the 10x chromium single cell 3' V2 library kit (10X Genomics) according to the
695 manufacturer's instructions and sequencing was performed on a NovaSeq 6000 System
696 (Illumina).

697

698 **Single-cell RNA sequencing data processing and analysis.**

699 Raw base call sequencing data were demultiplexed with Cellranger (v6.0.0) mkfastq
700 function and aligned by CellRanger (v6.0.0) count function using default settings and
701 the GRCh38-2020-A reference transcriptome from 10x Genomics. Summary by sample:
702 Parental control – 17,066 cells, 23,427 mean reads per cell, 2,370 median genes per
703 cell, 5,850 median UMI counts per cell; Proband – 10,542 cells, 37,722 mean reads per
704 cell, 3,300 median genes per cell, 9,578 median UMI counts per cell; GC control –
705 14,124 cells, 27,886 mean reads per cell, 2,780 median genes per cell, 6,556 median
706 UMI counts per cell. The count matrices were then converted to objects in Seurat v3.3.0
707 ^{64,65} for analysis and to generate visual representations. Standard quality control
708 parameters were applied to each object. In brief, cells with greater than 200 and less
709 than 5,000 unique features or less than 20% mitochondrial reads were retained. The
710 data were log-normalized with a scale factor of 10,000 and the top 2,000 variable
711 features per object were identified. Integration anchors were generated with 30 principal
712 components and used to integrate all samples into a combined object with a total of
713 35,633 cells. Standard Seurat procedures were applied to perform a principal
714 component analysis and KNN unbiased clustering. The FindNeighbors (PCA reduction,
715 30 dimensions) and FindClusters (0.5 resolution, 30 dimensions) functions were used to
716 identify 24 unbiased clusters. Cluster identities were determined by characteristic
717 canonical markers^{38,66-68} and 5 unique clusters were identified. Given the scope of the
718 study, we opted to utilize a subset object with 17,752 cells that exclusively contained
719 clusters relevant to our focus on progenitor-to-neuron differentiation. This subset object
720 contained immature neurons, intermediate progenitor cells, and three classes of neural
721 progenitor cells.

722

723 **Fetal brain and COs transcriptome analyses.**

724 Single-cell transcriptomic analyses of fetal brain cortex and COs were carried out on a
725 large, publicly available dataset¹⁹ (downloaded from
726 <https://cells.ucsc.edu/organoidreportcard/>). The data were handled in Seurat⁶⁴ (v3.2.2)
727 with R version 4.0.2 with a publicly available dataset. The fetal dataset was comprised
728 of 189,409 cells from various cortical regions of five unique fetal donors between weeks
729 6-22 of gestation. The organoid dataset was comprised of 235,121 cells from 37

730 organoids across a developmental time window spanning 3-10 weeks of culture. Cell
731 identities were assigned based on the meta data provided by Bhaduri et al.

732

733

734 **Statistical analyses.**

735 GraphPad Prism v9.0.0 (La Jolla, CA) was used to generate all graphs and perform all
736 data and statistical analyses in this study. For organoid growth analyses, the number of
737 replicates displayed in Figure 2 ranged from 19-53 from each group. Statistical analysis
738 of data of organoid growth was performed using a Mann-Whitney U test. Statistically
739 significant differences between parental control and proband COs were observed
740 between groups commencing at day 20, p values are displayed in Fig.2d. * $p \leq 0.05$; ** p
741 ≤ 0.01 ; *** $p \leq 0.001$; **** $p \leq 0.0001$; ns=not significant. For organoid growth analyses
742 in Fig.4r, the number of replicates ranged from 44-65 from each group at day 30.
743 Statistical analyses were performed using one-way ANOVA with Tukey's multiple
744 comparisons test (n = 14 rosettes quantified across a minimum of 4 independent
745 organoids per group and 1 independent experiment performed). Statistical analyses for
746 quantification of EdU+ and pHH3+ NPCs in neural rosettes of organoids was performed
747 using one-way ANOVA with Tukey's multiple comparisons test (minimum of n = 4
748 independent organoids per group and 3 independent experiments performed). Cilia
749 length quantifications in neural rosettes of organoids were performed using one-way
750 ANOVA with Tukey's multiple comparisons test (minimum of n = 4 independent
751 organoids per group and 1 independent experiment performed). Analysis of single-cell
752 RNA sequencing data are described in detail within the methods section. Eight
753 individual organoids were pooled per group consisting of parental control, proband and
754 GC control organoid groups. In all differential expression data analysis and Metascape
755 gene ontology analyses, p values were adjusted for multiple test correction. Significance
756 of differentially expressed genes was defined as adjusted $p < 0.05$.

757

758 **Acknowledgements**

759 We are grateful to all laboratory members for their advice and constructive critiques
760 related to this study. We would especially like to thank Arelis Berrios Hester for her

761 excellent editorial assistance. Figures 2 and 4 contain schematics that were created
762 with BioRender.com.

763

764 **Author Contributions**

765 S.R.F., W.S., D.J., T.B., and M.E.H. conceived and designed the experiments. S.R.F.,
766 W.S., M.E.H. D.J., J.W., T.B., K.E.M., P.W., D.C.K., R.N., and J.F performed the
767 research. S.R.F., M.E.H, W.S., D.J., J.W., T.B., K.E.M., P.W., D.C.K., R.N., S.R.,
768 M.N.K., S.E.H., and J.F analyzed the data. S.R.F., W.S., D.J., D.C.K., and M.E.H. wrote
769 the manuscript. All authors provided a critical review and approval of the final
770 manuscript for publication. This bench science and clinical research team works in the
771 Steve and Cindy Rasmussen Institute for Genomic Medicine at Nationwide Children's
772 Hospital. The institute is generously supported by the Nationwide Foundation Pediatric
773 Innovation Fund.

774

775 **Competing interests**

776 The authors report no competing interests.

777

778

779 **REFERENCES**

780

781 1 Sultana, R. *et al.* Identification of a novel gene on chromosome 7q11.2
782 interrupted by a translocation breakpoint in a pair of autistic twins. *Genomics* **80**,
783 129-134, doi:10.1006/geno.2002.6810 (2002).

784 2 Gao, Z. *et al.* An AUTS2-Polycomb complex activates gene expression in the
785 CNS. *Nature* **516**, 349-354, doi:10.1038/nature13921 (2014).

786 3 Beunders, G. *et al.* Exonic deletions in AUTS2 cause a syndromic form of
787 intellectual disability and suggest a critical role for the C terminus. *Am J Hum*
788 *Genet* **92**, 210-220, doi:10.1016/j.ajhg.2012.12.011 (2013).

789 4 Monderer-Rothkoff, G. *et al.* AUTS2 isoforms control neuronal differentiation. *Mol*
790 *Psychiatry* **26**, 666-681, doi:10.1038/s41380-019-0409-1 (2021).

791 5 Beunders, G. *et al.* A detailed clinical analysis of 13 patients with AUTS2
792 syndrome further delineates the phenotypic spectrum and underscores the
793 behavioural phenotype. *J Med Genet* **53**, 523-532, doi:10.1136/jmedgenet-2015-
794 103601 (2016).

795 6 Hori, K. *et al.* Cytoskeletal regulation by AUTS2 in neuronal migration and
796 neuritogenesis. *Cell Rep* **9**, 2166-2179, doi:10.1016/j.celrep.2014.11.045 (2014).

797 7 Schumann, G. *et al.* Genome-wide association and genetic functional studies
798 identify autism susceptibility candidate 2 gene (AUTS2) in the regulation of
799 alcohol consumption. *Proc Natl Acad Sci U S A* **108**, 7119-7124,
800 doi:10.1073/pnas.1017288108 (2011).

801 8 Chen, Y. H., Liao, D. L., Lai, C. H. & Chen, C. H. Genetic analysis of AUTS2 as a
802 susceptibility gene of heroin dependence. *Drug Alcohol Depend* **128**, 238-242,
803 doi:10.1016/j.drugalcdep.2012.08.029 (2013).

804 9 Mefford, H. C. *et al.* Genome-wide copy number variation in epilepsy: novel
805 susceptibility loci in idiopathic generalized and focal epilepsies. *PLoS Genet* **6**,
806 e1000962, doi:10.1371/journal.pgen.1000962 (2010).

807 10 Zhang, B. *et al.* Association study identifying a new susceptibility gene (AUTS2)
808 for schizophrenia. *Int J Mol Sci* **15**, 19406-19416, doi:10.3390/ijms151119406
809 (2014).

810 11 Ozsoy, F., Karakus, N. B., Yigit, S. & Kulu, M. Effect of AUTS2 gene rs6943555
811 variant in male patients with schizophrenia in a Turkish population. *Gene* **756**,
812 144913, doi:10.1016/j.gene.2020.144913 (2020).

813 12 Talkowski, M. E. *et al.* Sequencing chromosomal abnormalities reveals
814 neurodevelopmental loci that confer risk across diagnostic boundaries. *Cell* **149**,
815 525-537, doi:10.1016/j.cell.2012.03.028 (2012).

816 13 Girirajan, S. *et al.* Relative burden of large CNVs on a range of
817 neurodevelopmental phenotypes. *PLoS Genet* **7**, e1002334,
818 doi:10.1371/journal.pgen.1002334 (2011).

819 14 Castanza, A. S. *et al.* AUTS2 Regulates RNA Metabolism and Dentate Gyrus
820 Development in Mice. *Cereb Cortex*, doi:10.1093/cercor/bhab124 (2021).

- 821 15 Oksenberg, N., Stevison, L., Wall, J. D. & Ahituv, N. Function and regulation of
822 AUTS2, a gene implicated in autism and human evolution. *PLoS Genet* **9**,
823 e1003221, doi:10.1371/journal.pgen.1003221 (2013).
- 824 16 Hori, K. *et al.* AUTS2 Regulation of Synapses for Proper Synaptic Inputs and
825 Social Communication. *iScience* **23**, 101183, doi:10.1016/j.isci.2020.101183
826 (2020).
- 827 17 Pollen, A. A. *et al.* Establishing Cerebral Organoids as Models of Human-Specific
828 Brain Evolution. *Cell* **176**, 743-756.e717, doi:10.1016/j.cell.2019.01.017 (2019).
- 829 18 Camp, J. G. *et al.* Human cerebral organoids recapitulate gene expression
830 programs of fetal neocortex development. *Proc Natl Acad Sci U S A* **112**, 15672-
831 15677, doi:10.1073/pnas.1520760112 (2015).
- 832 19 Bhaduri, A. *et al.* Cell stress in cortical organoids impairs molecular subtype
833 specification. *Nature* **578**, 142-148, doi:10.1038/s41586-020-1962-0 (2020).
- 834 20 Eze, U. C., Bhaduri, A., Haeussler, M., Nowakowski, T. J. & Kriegstein, A. R.
835 Single-cell atlas of early human brain development highlights heterogeneity of
836 human neuroepithelial cells and early radial glia. *Nat Neurosci* **24**, 584-594,
837 doi:10.1038/s41593-020-00794-1 (2021).
- 838 21 Lancaster, M. A. *et al.* Cerebral organoids model human brain development and
839 microcephaly. *Nature* **501**, 373-379, doi:10.1038/nature12517 (2013).
- 840 22 Zhang, W. *et al.* Modeling microcephaly with cerebral organoids reveals a
841 WDR62-CEP170-KIF2A pathway promoting cilium disassembly in neural
842 progenitors. *Nat Commun* **10**, 2612, doi:10.1038/s41467-019-10497-2 (2019).
- 843 23 Wang, L. *et al.* Loss of NARS1 impairs progenitor proliferation in cortical brain
844 organoids and leads to microcephaly. *Nat Commun* **11**, 4038,
845 doi:10.1038/s41467-020-17454-4 (2020).
- 846 24 Gabriel, E., Ramani, A., Altinisik, N. & Gopalakrishnan, J. Human Brain
847 Organoids to Decode Mechanisms of Microcephaly. *Front Cell Neurosci* **14**, 115,
848 doi:10.3389/fncel.2020.00115 (2020).
- 849 25 Doobin, D. J., Kemal, S., Dantas, T. J. & Vallee, R. B. Severe NDE1-mediated
850 microcephaly results from neural progenitor cell cycle arrests at multiple specific
851 stages. *Nat Commun* **7**, 12551, doi:10.1038/ncomms12551 (2016).
- 852 26 Merfeld, E., Ben-Avi, L., Kennon, M. & Cervený, K. L. Potential mechanisms of
853 Zika-linked microcephaly. *Wiley Interdiscip Rev Dev Biol* **6**,
854 doi:10.1002/wdev.273 (2017).
- 855 27 Kopanos, C. *et al.* VarSome: the human genomic variant search engine.
856 *Bioinformatics* **35**, 1978-1980, doi:10.1093/bioinformatics/bty897 (2019).
- 857 28 Fair, S. R. *et al.* Electrophysiological Maturation of Cerebral Organoids
858 Correlates with Dynamic Morphological and Cellular Development. *Stem Cell*
859 *Reports* **15**, 855-868, doi:10.1016/j.stemcr.2020.08.017 (2020).
- 860 29 Qian, X. *et al.* Brain-Region-Specific Organoids Using Mini-bioreactors for
861 Modeling ZIKV Exposure. *Cell* **165**, 1238-1254, doi:10.1016/j.cell.2016.04.032
862 (2016).
- 863 30 Hill, R. S. & Walsh, C. A. Molecular insights into human brain evolution. *Nature*
864 **437**, 64-67, doi:10.1038/nature04103 (2005).

- 865 31 Kriegstein, A., Noctor, S. & Martinez-Cerdeno, V. Patterns of neural stem and
866 progenitor cell division may underlie evolutionary cortical expansion. *Nat Rev*
867 *Neurosci* **7**, 883-890, doi:10.1038/nrn2008 (2006).
- 868 32 Penisson, M., Ladewig, J., Belvindrah, R. & Francis, F. Genes and Mechanisms
869 Involved in the Generation and Amplification of Basal Radial Glial Cells. *Front*
870 *Cell Neurosci* **13**, 381, doi:10.3389/fncel.2019.00381 (2019).
- 871 33 Gabriel, E. *et al.* Recent Zika Virus Isolates Induce Premature Differentiation of
872 Neural Progenitors in Human Brain Organoids. *Cell stem cell* **20**, 397-406 e395,
873 doi:10.1016/j.stem.2016.12.005 (2017).
- 874 34 Gabriel, E. *et al.* CPAP promotes timely cilium disassembly to maintain neural
875 progenitor pool. *EMBO J* **35**, 803-819, doi:10.15252/embj.201593679 (2016).
- 876 35 Jayaraman, D. *et al.* Microcephaly Proteins Wdr62 and Aspm Define a Mother
877 Centriole Complex Regulating Centriole Biogenesis, Apical Complex, and Cell
878 Fate. *Neuron* **92**, 813-828, doi:10.1016/j.neuron.2016.09.056 (2016).
- 879 36 Shohayeb, B. *et al.* The association of microcephaly protein WDR62 with
880 CPAP/IFT88 is required for cilia formation and neocortical development. *Hum*
881 *Mol Genet* **29**, 248-263, doi:10.1093/hmg/ddz281 (2020).
- 882 37 Sivitilli, A. A. *et al.* Robust production of uniform human cerebral organoids from
883 pluripotent stem cells. *Life Sci Alliance* **3**, doi:10.26508/lsa.202000707 (2020).
- 884 38 Velasco, S. *et al.* Individual brain organoids reproducibly form cell diversity of the
885 human cerebral cortex. *Nature*, doi:10.1038/s41586-019-1289-x (2019).
- 886 39 Arai, Y. *et al.* Role of Fabp7, a downstream gene of Pax6, in the maintenance of
887 neuroepithelial cells during early embryonic development of the rat cortex. *J*
888 *Neurosci* **25**, 9752-9761, doi:10.1523/JNEUROSCI.2512-05.2005 (2005).
- 889 40 Jo, A. *et al.* The versatile functions of Sox9 in development, stem cells, and
890 human diseases. *Genes Dis* **1**, 149-161, doi:10.1016/j.gendis.2014.09.004
891 (2014).
- 892 41 Kaplan, E. S., Ramos-Laguna, K. A., Mihalas, A. B., Daza, R. A. M. & Hevner, R.
893 F. Neocortical Sox9+ radial glia generate glutamatergic neurons for all layers, but
894 lack discernible evidence of early laminar fate restriction. *Neural Dev* **12**, 14,
895 doi:10.1186/s13064-017-0091-4 (2017).
- 896 42 Wiszniak, S. & Schwarz, Q. Notch signalling defines dorsal root ganglia
897 neuroglial fate choice during early neural crest cell migration. *BMC Neurosci* **20**,
898 21, doi:10.1186/s12868-019-0501-0 (2019).
- 899 43 Kishi, Y., Fujii, Y., Hirabayashi, Y. & Gotoh, Y. HMGA regulates the global
900 chromatin state and neurogenic potential in neocortical precursor cells. *Nat*
901 *Neurosci* **15**, 1127-1133, doi:10.1038/nn.3165 (2012).
- 902 44 Ohtsuka, T. & Kageyama, R. Regulation of temporal properties of neural stem
903 cells and transition timing of neurogenesis and gliogenesis during mammalian
904 neocortical development. *Semin Cell Dev Biol* **95**, 4-11,
905 doi:10.1016/j.semcdb.2019.01.007 (2019).
- 906 45 Oksenberg, N. *et al.* Genome-wide distribution of Auts2 binding localizes with
907 active neurodevelopmental genes. *Transl Psychiatry* **4**, e431,
908 doi:10.1038/tp.2014.78 (2014).
- 909 46 Chenn, A. Wnt/beta-catenin signaling in cerebral cortical development.
910 *Organogenesis* **4**, 76-80, doi:10.4161/org.4.2.5852 (2008).

- 911 47 Machon, O., van den Bout, C. J., Backman, M., Kemler, R. & Krauss, S. Role of
912 beta-catenin in the developing cortical and hippocampal neuroepithelium.
913 *Neuroscience* **122**, 129-143, doi:10.1016/s0306-4522(03)00519-0 (2003).
- 914 48 Woodhead, G. J., Mutch, C. A., Olson, E. C. & Chenn, A. Cell-autonomous beta-
915 catenin signaling regulates cortical precursor proliferation. *J Neurosci* **26**, 12620-
916 12630, doi:10.1523/JNEUROSCI.3180-06.2006 (2006).
- 917 49 Shtutman, M. *et al.* The cyclin D1 gene is a target of the beta-catenin/LEF-1
918 pathway. *Proc Natl Acad Sci U S A* **96**, 5522-5527, doi:10.1073/pnas.96.10.5522
919 (1999).
- 920 50 Tetsu, O. & McCormick, F. Beta-catenin regulates expression of cyclin D1 in
921 colon carcinoma cells. *Nature* **398**, 422-426, doi:10.1038/18884 (1999).
- 922 51 Bohrer, C. *et al.* The balance of Id3 and E47 determines neural stem/precursor
923 cell differentiation into astrocytes. *EMBO J* **34**, 2804-2819,
924 doi:10.15252/embj.201591118 (2015).
- 925 52 Wu, Y., Liu, Y., Levine, E. M. & Rao, M. S. Hes1 but not Hes5 regulates an
926 astrocyte versus oligodendrocyte fate choice in glial restricted precursors. *Dev*
927 *Dyn* **226**, 675-689, doi:10.1002/dvdy.10278 (2003).
- 928 53 Autism Genome Project, C. *et al.* Mapping autism risk loci using genetic linkage
929 and chromosomal rearrangements. *Nat Genet* **39**, 319-328, doi:10.1038/ng1985
930 (2007).
- 931 54 Dean, C. *et al.* Neurexin mediates the assembly of presynaptic terminals. *Nat*
932 *Neurosci* **6**, 708-716, doi:10.1038/nn1074 (2003).
- 933 55 Deardorff, M. A. *et al.* Mutations in cohesin complex members SMC3 and
934 SMC1A cause a mild variant of cornelia de Lange syndrome with predominant
935 mental retardation. *Am J Hum Genet* **80**, 485-494, doi:10.1086/511888 (2007).
- 936 56 Skaar, D. A. *et al.* Analysis of the RELN gene as a genetic risk factor for autism.
937 *Mol Psychiatry* **10**, 563-571, doi:10.1038/sj.mp.4001614 (2005).
- 938 57 Wu, Y. *et al.* Multi-trait analysis for genome-wide association study of five
939 psychiatric disorders. *Transl Psychiatry* **10**, 209, doi:10.1038/s41398-020-00902-
940 6 (2020).
- 941 58 Hasenpusch-Theil, K. *et al.* Transcriptional analysis of Gli3 mutants identifies
942 Wnt target genes in the developing hippocampus. *Cereb Cortex* **22**, 2878-2893,
943 doi:10.1093/cercor/bhr365 (2012).
- 944 59 Dubruc, E. *et al.* A new intellectual disability syndrome caused by CTNNB1
945 haploinsufficiency. *Am J Med Genet A* **164A**, 1571-1575,
946 doi:10.1002/ajmg.a.36484 (2014).
- 947 60 Kuechler, A. *et al.* De novo mutations in beta-catenin (CTNNB1) appear to be a
948 frequent cause of intellectual disability: expanding the mutational and clinical
949 spectrum. *Hum Genet* **134**, 97-109, doi:10.1007/s00439-014-1498-1 (2015).
- 950 61 Sanxiong Liu, K. A. A., Chi Vicky Cheng, Takae Kiyama, Mitali Dave, Hanna K.
951 McNamara, Stefano G Caraffi, Ivan Ivanovski, Edoardo Errichiello, Christiane
952 Zweier, Orsetta Zuffardi, Michael Schneider, Antigone S. Papavasiliou, M. Scott
953 Perry, Megan T Cho, Astrid Weber, Andrew Swale, Tudor C. Badea, Chai-An
954 Mao, Livia Garavelli, William B Dobyns, Danny Reinberg. NRF1 Association with
955 AUTS2-Polycomb Mediates Specific Gene Activation in the Brain. *BioRxiv*
956 <https://www.biorxiv.org/content/10.1101/2021.03.30.437620v1.full> (2021).

- 957 62 Cingolani, P. *et al.* A program for annotating and predicting the effects of single
958 nucleotide polymorphisms, SnpEff: SNPs in the genome of *Drosophila*
959 *melanogaster* strain w1118; iso-2; iso-3. *Fly (Austin)* **6**, 80-92,
960 doi:10.4161/fly.19695 (2012).
- 961 63 Koboldt, D. C. *et al.* A de novo nonsense mutation in ASXL3 shared by siblings
962 with Bainbridge-Ropers syndrome. *Cold Spring Harb Mol Case Stud* **4**,
963 doi:10.1101/mcs.a002410 (2018).
- 964 64 Stuart, T. *et al.* Comprehensive Integration of Single-Cell Data. *Cell* **177**, 1888-
965 1902.e1821, doi:10.1016/j.cell.2019.05.031 (2019).
- 966 65 Butler, A., Hoffman, P., Smibert, P., Papalexi, E. & Satija, R. Integrating single-
967 cell transcriptomic data across different conditions, technologies, and species.
968 *Nature Biotechnology* **36**, 411-420, doi:10.1038/nbt.4096 (2018).
- 969 66 Quadrato, G. *et al.* Cell diversity and network dynamics in photosensitive human
970 brain organoids. *Nature* **545**, 48-53, doi:10.1038/nature22047 (2017).
- 971 67 Xiang, Y. *et al.* Fusion of Regionally Specified hPSC-Derived Organoids Models
972 Human Brain Development and Interneuron Migration. *Cell stem cell* **21**, 383-398
973 e387, doi:10.1016/j.stem.2017.07.007 (2017).
- 974 68 Cakir, B. *et al.* Engineering of human brain organoids with a functional vascular-
975 like system. *Nat Methods* **16**, 1169-1175, doi:10.1038/s41592-019-0586-5
976 (2019).

977
978

979 Figure legends

980

981 **Figure 1. Identification of a *de novo* *AUTS2* variant within a conserved histidine**
982 **rich domain. (A)** Family pedigree. Circle: female; square: male; filled: affected. **(B-C)**
983 MRI of affected individual showing reduced cortical area, ventriculomegaly (asterisk)
984 and cerebellar atrophy (arrow). MRI images are arranged in sagittal and coronal planes,
985 respectively. Scale bar = 2 cm. **(D)** Sanger-based DNA sequence chromatogram of the
986 c.1600A>C *AUTS2* variant in exon 9 in the affected patient and absent in her
987 unaffected, healthy parents. **(E)** *AUTS2* genomic organization showing disease-causing
988 variants, key domains, and exon structure of the *AUTS2* gene. Pathogenic and likely
989 pathogenic variants from the ClinVar database as of January 2021 are represented by
990 circles and shaded according to variant classes. Proline-rich domains (PR1/PR2) and
991 histidine-rich domains (H1/H2) were obtained from UniProt (entry Q8WXX7). The
992 curated *AUTS2* protein family domain from PFAM is shown in yellow. Exon locations
993 and numbering in the bottom panel reflect the canonical full-length transcript
994 (NM_015570.4). **(F)** *AUTS2* amino acid conservation within the H1 domain and

995 spanning position 534 across multiple species. Arrow represents the *AUTS2* T534P
996 alteration in the affected patient.

997

998 **Figure 2. *AUTS2* patient COs show reduced growth and proliferative deficits. (A)**

999 Overview of protocol used to generate COs. Briefly, peripheral blood mononuclear cells
1000 (PBMCs) were isolated from patient and control blood samples and underwent Sendai
1001 virus transduction with Yamanaka factors (OCT3/4, SOX2, KLF4, c-MYC) to produce
1002 induced pluripotent stem cells (iPSCs). These cultures were characterized and then
1003 used to generate COs through undirected, spontaneous differentiation. **(B-C)**
1004 Representative images of parental control COs and proband COs at Day 34 showing a
1005 significant growth reduction in proband COs. Scale bar = 1 mm. **(D)** Growth trajectory
1006 analysis of parental control and proband COs from days 16-37 in CO development. **(E-**
1007 **F)** Parental control COs show proliferating neural progenitors identified as EdU+ and
1008 phospho-Histone H3+ (pHH3; mitosis marker) compared to proband COs, which show a
1009 reduction (quantified in **G** and **H**). Scale bar = 50 μ m. DAPI (blue) stains nuclei. All data
1010 are shown as the mean \pm standard deviation (SD). Statistical analyses in panel d were
1011 performed using Mann-Whitney U tests and those in panels g and h were performed
1012 using one-way ANOVA with Tukey's multiple comparisons test (n = 4 independent
1013 organoids per group and 2 independent experiments performed). Statistically significant
1014 differences between parental control and proband COs were observed between groups
1015 commencing at day 20. *p \leq 0.05; **p \leq 0.01; ***p \leq 0.001; ****p \leq 0.0001.

1016

1017 **Figure 3. *AUTS2* patient COs show functional and molecular deficits in neural**

1018 **progenitor cells. (A)** The fate of neural progenitor daughter cells correlates with their
1019 mitotic division class. Symmetric divisions (top) give rise to two daughter apical
1020 progenitors whereas asymmetric divisions (bottom) give rise to a single apical
1021 progenitor and one mature cell type (intermediate progenitor or neuron). **(B-C)**
1022 Representative mitotic divisions at the apical surface of parental control and proband
1023 rosettes of COs. The division class is determined by the acute angle, θ_a , that forms
1024 between the cleavage plane (defined by TPX2+ mitotic poles, green) and the apical
1025 surface (marked by ZO1, red). Cell nuclei visualized with DAPI (blue). Scale bar = 50

1026 μm and $10 \mu\text{m}$ for lower and higher magnification images, respectively. **(D)** Asymmetric
1027 oblique and vertical divisions are overrepresented in proband COs (65%) compared to
1028 parental control COs (36%). **(E-F)** Acetylated tubulin (AcTub) staining reveals normal
1029 rosette microtubular organization within parental control COs, but severely disrupted
1030 organization in proband COs **(G-H)**. Scale bar = $250 \mu\text{m}$. **(I)** SOX2+ neural progenitors
1031 (red) within rosettes of parental control COs form robust, uniform ARLB13B+ cilia
1032 (green) at the apical surface, whereas those within rosettes of proband COs show
1033 shortened and irregular arrangement **(J)**. Scale bar = $10 \mu\text{m}$. **(K)** Proband cilia show a
1034 statistically significant reduction in length compared to parental control cilia. All data are
1035 shown as the mean \pm SD. Statistical analysis of cilia quantification data was performed
1036 using an unpaired t-test ($n = 540$ parental control cilia and $n = 191$ proband cilia quantified
1037 across 4 independent organoids per group and 1 independent experiment performed).
1038 **** $p \leq 0.0001$.

1039

1040 **Figure 4. *AUTS2* gene editing with CRISPR-Cas9 rescues proband COs**
1041 **phenotypes. (A)** CRISPR-Cas9-mediated homology directed repair gene correction
1042 strategy **(B)** Chromatogram generated by Sanger sequencing of affected patient
1043 (*AUTS2* c.1600A>C, proband) and GC hiPSC line. First arrow denotes the C>A base
1044 pair change at c.1600 and the second arrow denotes the silent gene edit (G>A) at
1045 c.1608. **(C-G)** Schematic showing major steps in an optimized protocol to generate
1046 reproducible COs from hiPSCs with representative culture phase contrast microscopic
1047 images below each step. Scale bar = $200 \mu\text{m}$ and $500 \mu\text{m}$ for **(D)** and **(E-G)**,
1048 respectively. **(H,I,J)** Representative images of parental control, proband, and GC control
1049 COs at Day 30, cross-sectional area of each CO group quantified in **(Q)**. **(K,L,M)**
1050 Decreased percentage of EdU+ and phospho-Histone H3+ (pHH3; red, mitosis marker)
1051 progenitors in proband CO rosettes compared to parental and GC controls. Scale bar =
1052 $200 \mu\text{m}$. Magnified in **(N)**, **(O)** and **(P)**, scale bar = $50 \mu\text{m}$; quantified in **(R)** and **(S)**. All
1053 data are shown as the mean \pm SD. Statistical analyses were performed using one-way
1054 ANOVA with Tukey's multiple comparisons test ($n = 14$ rosettes quantified across a
1055 minimum of 4 independent organoids per group and 1 independent experiment
1056 performed). *** $p \leq 0.001$; **** $p \leq 0.0001$; ns=not significant.

1057

1058 **Figure 5. Single-cell RNA sequencing reveals an underrepresented population of**
1059 **proliferative neural progenitor cells in proband COs. (A)** UMAP plot of key cell types
1060 organized into five major clusters: Intermediate progenitors, immature neurons, and
1061 three classes of neural progenitor cells containing 17,752 cells. **(B)** Select canonical
1062 markers used to determine cluster identities. *MKI67* and *TOP2A* show enriched
1063 expression within Type 1 neural progenitor cells, *CDK6* shows enriched expression in
1064 Type 2 neural progenitor cells and *SOX9* shows enriched expression in Type 3 neural
1065 progenitor cells; *SOX2* is a pan-progenitor marker; *EOMES (TBR2)* labels Intermediate
1066 Progenitors; *STMN2* and *TBR1* label Immature Neurons. **(C-E)** UMAP plots of cells from
1067 parental control COs (8,523 cells), proband COs (3,754 cells) and GC control COs
1068 (5,475 cells). Type 2 neural progenitors are outlined in each plot to highlight their
1069 underrepresentation in proband COs. **(F-H)** Percentages of cell types per group. **(I)** GO
1070 terms identified in Type 2 neural progenitors enriched for genes associated with G1/S
1071 cell cycle phase transition. (source: Metascape) **(J)** Differentially expressed genes and
1072 associated information identified in the G1/S transition of the mitotic cell cycle gene
1073 ontology. **(K)** Feature plots showing expression of G1/S cell cycle genes in proband and
1074 GC control COs.

1075

1076 **Figure 6. Deficits in WNT- β Catenin pathway gene expression in *AUTS2* patient**
1077 **COs. (A)** GO terms identified in Type 1 neural progenitors enriched for genes
1078 associated with the WNT- β Catenin signaling among others. **(B)** Violin plots of DEGs in
1079 Type 1 neural progenitors shows chromatin modifying genes: *HIST1H2AG*,
1080 *KCNQ10T1*, and *HMGA1*; transcriptional regulator, *TSHZ2*, which has been identified
1081 as an *AUTS2* target gene; and genes associated with neural and glial differentiation:
1082 *FGFR3*, *NFIB*, *MAP2*; and cell adhesion: *CNTNAP2*, also identified as an *AUTS2* target
1083 gene. **(C)** Heat maps of Type 1 neural progenitor DEGs in proband and control COs
1084 show alterations in gene expression associated with WNT- β Catenin signaling. Feature
1085 and violin plots of *CTNNB1* gene expression in Type 1 and 3 neural progenitors, and
1086 immature neurons shows reduced expression in proband COs compared to controls.
1087 **(D)** Schematic showing the WNT- β Catenin pathway and color-coded Type 1 neural


1088 progenitor DEGs (Red=up-regulated and green=down-regulated). **(E)** GO terms
1089 identified in Type 3 neural progenitors enriched for genes associated with the canonical
1090 WNT signaling pathway, regulation of glial cell differentiation, and others. **(F)** Violin plots
1091 of DEGs in Type 3 neural progenitors show NOTCH signaling transcription factor,
1092 *HES1*, and *ID3*, which regulate glial differentiation; genes regulating cellular division:
1093 *CENPF* and *CENPW*; chromatin modifying gene, *HMGA1*; and WNT signaling
1094 regulators: *RSPO3*, *SFRP2*, and *ZIC1* **(G)** GO terms identified in immature neurons
1095 enriched for genes associated with synapse maturation, cholesterol metabolism,
1096 cytoskeletal organization, and others. **(H)** Violin plots of DEGs in immature neurons
1097 shows genes associated with synapse maturation: *NEFM*, *RELN*, and *NRXN1*;
1098 cholesterol biosynthesis: *ACAT2* and *HMGCS1*; and genes associated with cytoskeletal
1099 organization: *SMC1A* and *NEFM*; and neurite morphogenesis: *DCC* and *MDK*. Of note,
1100 *NRXN1* (AUTS2 target gene), *DCC*, *RELN* (AUTS2 target gene), and *SMC1A* are also
1101 designated SFARI genes implicated in autism spectrum disorder and intellectual
1102 disability. Log₂ fold changes (FC) are shown under each violin plot and denote FC
1103 relative to either the parental control or gene corrected control.

1104




1105

Figure 1


a *AUTS2* de novo missense variant



c.1600A>C
p.T534P



e



f




Figure 2








Figure 3




Figure 4




Figure 5




Figure 6